Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-11-02
2009-10-06
Hobbs, Lisa J (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S445000
Reexamination Certificate
active
07598220
ABSTRACT:
This invention relates to the use of hypo-oncotic aqueous solutions of molecularly dispersed chemically modified high molecular weight crosslinked hemoglobins, namely so-called hemoglobin hyperpolymers, to prepare agents for the symptomatic, primarily life-saving treatment of acute pulmonary edema. Administration in particular is intravascular. Surprisingly, additive administration can be performed since according to the invention the colloidal-osmotic (=oncotic) pressure of the blood itself is essentially raised only slightly, and the blood volume is increased hardly at all. Administration pursuant to the invention is thus (almost) volume-neutral based on the blood into which the injection is made. A hyperpolymeric hemoglobin derivative is thus used therapeutically for the first time as a blood additive for the treatment of pulmonary edema.
REFERENCES:
patent: 5234903 (1993-08-01), Nho et al.
patent: 5665383 (1997-09-01), Grinstaff et al.
patent: 5985332 (1999-11-01), Barnikol et al.
patent: 6432918 (2002-08-01), Winslow
patent: 2004/0022839 (2004-02-01), Barnikol
patent: 2004/0242846 (2004-12-01), Barnikol
patent: 197 01 37 (1967-10-01), None
patent: 37 14 351 (1988-11-01), None
patent: 35 76 651 (1990-04-01), None
patent: 38 41 105 (1990-06-01), None
patent: 44 18 937 (1995-08-01), None
patent: 44 18 973 (1995-12-01), None
patent: 197 01 037 (1998-07-01), None
patent: 100 31 742 (2002-01-01), None
patent: 100 31 744 (2002-01-01), None
patent: 100 31 740 (2002-02-01), None
patent: 97 100 790 (1983-01-01), None
patent: WO 02/00230 (2002-01-01), None
patent: WO 02/00768 (2002-01-01), None
patent: WO 03/094953 (2003-11-01), None
Riess, J.G.: “Oxygen Carriers (Blood Substitutes)—Raison d'Etre, Chemistry, and some Physiology,” Chemical Reviews 101 (2001): 2797-2919. (pp. 2797-2800 enclosed).
Böcker, W., Denk, H., Heitz Ph. U (Ed.): Pathology, Urban & Schwarzenberg, Munich and elsewhere 1997; (Spec. p. 6) (Front Page and List of Contents Enclosed).
Gerok W., Huber C., Meinertz T., Zeidler, H. (Ed.): Gross-Schölmerich-Gerock-Die Innere Medizin, 10thcompletely new revision and expanded edition, Schattauer, Stuttgart and New York 2000.(Spec. pp. 6-7). (Front page and List of contents Enclosed).
Weihrauch, T.R. (Ed.): Wolff-Weihrauch-Internistische Therapie 2000/2001, 13threvised edition, Urban & Fisher, Munich, and Jena 2000 (Spec. p. 7) (Front page and List of contents Enclosed).
Vazquez, R.M., “Nursing care for the patient . . . ,” Arch. Cardio. Mex., vol. 72, pp. 280-285 (Spec. p. 7) (English Abstract).
Katren V.: “The Conjugation of Proteins with Polyethylene Glycol and Other Polymers—Altering Properties of Proteins to Enhance Their Therapeutic Potential,” Advanced Drug Delivery Reviews 10 (1993): 91-114) (Spec. p. 9).
Vandegriff KD: “Haemoglobin-Based Oxygen Carriers” Expert Opinion on Investigational Drugs, Ashley Publications Ltd., London, GB, vol. 9,-No. 9, 2000, pp. 1967-1984, XP008034792, ISSN: 1354-3784.
Barnikol et al: “Hyperpolymere Hämoglobine als künstliche Sauerstoffträger” Therapiewoche, vol. 15, 1996, pp. 811-815, XP09044173.
Barnikol Wolfgang K R et al: “New artificial oxygen carriers made of pegulated polymerised pyridoxylated porcine haemoglobin (P4Hb)” Comparative Biochemistry and Physiology Part A Molecular and Integrative Physiology, vol. 132A, No. 1, May 2002, pp. 185-191, XP002318526 ISSN: 1095-6433.
Vandegriff KD: “Haemoglobin-Based Oxygen Carriers” Expert Opinion on Investigational Drugs, Ashley Publications Ltd., London, GB, vol. 9, No. 9, 2000, pp. 1967-1984, XP008034792, ISSN: 1354-3784.
Barnikol WK R et al: “Haemoglobin hyperpolymers, a new type of artificial oxygen carrier—Concept and current state of development” Transfusion Medicine and Hemotherapy, vol. 31, No. 4, Aug. 2004, pp. 269-281, XP 009044191 ISSN: 1660-3796.
Riess, J.G.: “Oxygen Carriers (Blood Substitutes)—Raison d'Etre, Chemistry, and some Physiology,” Chemical Reviews 101 (2001): 2797-2919. (Spec p. 2) to follow.
Böcker, W., Denk, H., Heitz Ph. U (Ed.): Pathology, Urban & Schwarzenberg, Munich and elsewhere 1997; (Spec. p. 6) to follow.
Gerock W., Hube CH, Meinertz T., Zeidler, H. (Ed.): Gross-Schölmerich-Gerock-Die Innere Medizin, 10thcompletely new revision and expanded edition, Schattauer, Stuttgart and New York 2000. (Spec. pp. 6-7). to follow.
Weikrauch, T.R. (Ed.): Wolff-Weikrauch-Internistische Therapie 2000/2001, 13threvised edition, Urban & Fisher, Munich, and Jena 2000 (Spec. p. 7) to follow.
Arch. Cardio. Mex., vol. 72, pp. 280-285 (Spec. p. 7) to follow.
Katren, V.: “The Conjugation of Proteins with Polyethylene Glycol and Other Polymers—Altering Properties of Proteins to Enhance Their Therapeutic Potential,” Advanced Drug Delivery Reviews 10 (1993): 91-114) (Spec. p. 9) to follow.
Pötzschke H. et al. (1997): “Molar Masses and Structure in Solution of Haemoglobin Hyperpolymers—A Common Calibration of Size Exclusion Chromatography of These Artificial Oxygen Carriers,” Artificial Cells, Blood Substitutes, and Immobilization Biotechnology 25, 527-540) on Sephacryl S-400 HR gel (Pharmacia Biotech, Freiburg, Germany) (Spec. p. 24) to follow.
Collard & Roe P.C.
Hobbs Lisa J
SanguiBio Tech GmbH
LandOfFree
Use of hyperpolymeric hemoglobin for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hyperpolymeric hemoglobin for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hyperpolymeric hemoglobin for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095943